GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Windlas Biotech Ltd

Windlas Biotech Q2 FY27 Net Profit at INR 180.52 million, Hitesh Windlass Appointed Chairman

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 05 Nov 2026, 04:27 PM IST  ·  BSE ID: 6b8e68c3-f476-4130-8aa9-3128229c3ee9
View Original BSE Filing (PDF)
💡
In Simple Terms
Windlas Biotech announced its financial results, showing INR 180.52 million profit, and appointed a new Chairman for its Board.
🤖 AI Summary
  • Windlas Biotech's Profit for the period for Q2 FY27 was INR 180.52 million, for the six months ended September 30, 2026, it was INR 357.05 million.
  • Revenue from Operations for Q2 FY27 reached INR 2,639.08 million; six-month revenue totaled INR 5,120.07 million.
  • The Board approved Mr. Hitesh Windlass's appointment as Chairman of the Board, effective November 5, 2026.
  • Mr. Ashok Kumar Windlass resigned as Whole-time Director and Director due to succession planning, effective November 5, 2026.
  • Mr. Ashok Kumar Windlass was appointed as Senior Management Personnel, effective November 6, 2026, subject to shareholder approval.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from Operations (Q2 FY27)
2,639.08 million
18.66
Profit for the period (Q2 FY27)
180.52 million
1.42
Basic EPS (Q2 FY27)
8.75 Rs.
3.18
Revenue from Operations (Six months ended Sept 30, 2026)
5,120.07 million
18.39
Profit for the period (Six months ended Sept 30, 2026)
357.05 million
0.68
🏢 How This Affects the Company
📈
Business Impact
The company's reported revenue from operations for Q2 FY27 was INR 2,639.08 million, indicating ongoing business activity in its pharmaceutical segment. Consolidated financial statements are no longer being prepared from April 1, 2026, due to the dissolution of Windlas Inc., USA.
💰
Financial Impact
Profit for the period for Q2 FY27 was INR 180.52 million. Basic Earnings Per Share (EPS) for Q2 FY27 was Rs. 8.75, compared to Rs. 8.48 for Q2 FY26.
⚙️
Operational Impact
The company completed a buyback of 470,000 equity shares at Rs. 1,000 per share, amounting to INR 470,000,000. This reduced the paid-up equity share capital to 20,636,229 equity shares.
👥 What This Means For Shareholders
✅
Action Required
Shareholders are not required to take immediate action based on this financial results and board appointment disclosure.
👤
Who Is Affected
Existing shareholders benefit from the reported financial performance and the stability of Board leadership. Shareholders will need to approve Mr. Ashok Kumar Windlass's appointment as Senior Management Personnel.
🔍
Management Signal
The management's decision to appoint Mr. Hitesh Windlass as Chairman and transition Mr. Ashok Kumar Windlass to Senior Management Personnel indicates a focus on succession planning and strategic leadership continuity.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — monitor revenue and profit trends.
Shareholder meeting outcome for Mr. Ashok Kumar Windlass's appointment.
Updates on the impact of new labour codes on financial statements.
LOW RISK The filing reports stable financial results and details planned leadership transitions within the company.
💡 Investor Takeaway
Windlas Biotech reported Q2 FY27 Revenue from Operations at INR 2,639.08 million, up from INR 2,223.98 million in Q2 FY26. Profit for the period was INR 180.52 million, compared to INR 178.00 million in Q2 FY26. Mr. Hitesh Windlass has been appointed Chairman of the Board.
⚖️ Strengths & Concerns

✅ Positives

  • Profit for the period for Q2 FY27 stood at INR 180.52 million, showing growth from INR 178.00 million in Q2 FY26.
  • Revenue from Operations for Q2 FY27 increased to INR 2,639.08 million from INR 2,223.98 million in Q2 FY26.

⚠️ Concerns

  • Profit before tax for Q2 FY27 was INR 233.00 million, a slight decrease from INR 235.88 million in Q2 FY26.
  • Employee Benefit Expenses for Q2 FY27 increased to INR 478.14 million from INR 364.45 million in Q2 FY26.
📅 Company Track Record
Windlas Biotech reported Q2 FY27 adjusted PAT rising 29% YoY to Rs. 25 crores (INR 250 million) and revenue at Rs. 264 crores (INR 2,640 million) in a related press release. The Q2 FY27 net profit reported in this filing is INR 180.52 million.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Windlas Biotech's Revenue from Operations in Q2 FY27?
Windlas Biotech reported Revenue from Operations of INR 2,639.08 million for the quarter ended September 30, 2026 (Q2 FY27).
What was Windlas Biotech's Profit for the period in Q2 FY27?
The Profit for the period for Windlas Biotech in Q2 FY27 was INR 180.52 million, compared to INR 178.00 million in Q2 FY26.
Who has been appointed Chairman of Windlas Biotech's Board?
Mr. Hitesh Windlass, Managing Director and Promoter, has been approved as the Chairman of the Board of Directors of Windlas Biotech, effective November 5, 2026.
What is the status of Mr. Ashok Kumar Windlass at Windlas Biotech?
Mr. Ashok Kumar Windlass resigned as Whole-time Director and Director effective November 5, 2026, but has been appointed as Senior Management Personnel effective November 6, 2026, subject to shareholder approval.
What was Windlas Biotech's Basic Earnings per Share (EPS) for Q2 FY27?
Windlas Biotech's Basic Earnings per Share (EPS) for Q2 FY27 was Rs. 8.75, compared to Rs. 8.48 for Q2 FY26.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.